文献速递生殖医学

不明原因不孕症一线治疗选择体外受精还是宫腔内人工授精:治疗选择标志物的难题

IVF or IUI as first-line treatment in unexplained subfertility: the conundrum of treatment selection markers.
PubMed 文献 · Hum Reprod · 2017-01-01

本研究基于INeS试验数据,分析不明原因或轻度男性不育夫妇中,是否有治疗选择标志物能识别出从体外受精单胚胎移植(IVF-SET)比从促排卵宫腔内人工授精(IUI-OS)获得健康孩子机会更高的夫妇。结果显示,预设的基线特征均未与IVF-SET相比IUI-OS获得健康孩子机会更高相关(交互作用P值>0.10)。作者结论认为未能识别出此类夫妇,鉴于IUI-OS效果相似且费用更低,应继续作为首选一线治疗。

要点

  • 预设的基线特征均未显示与IVF-SET相比IUI-OS获得健康孩子机会更高相关(交互作用P值>0.10)。
  • 作者结论认为未能识别出从立即IVF-SET比从IUI-OS获得健康孩子机会更高的不明原因或轻度男性不育夫妇。
  • 作者指出原试验中IUI-OS效果相似且费用更低,应继续作为这些夫妇的首选一线治疗。

核心结论

  • 未发现任何治疗选择标志物与不明原因或轻度男性不育夫妇从IVF-SET而非IUI-OS获得健康孩子机会更高相关。
  • 作者结论认为未能识别出从立即IVF-SET比从IUI-OS获得健康孩子机会更高的夫妇,IUI-OS应继续作为首选一线治疗。

研究设计与样本

  • 基于INeS试验数据的分析,该试验将不明原因或轻度男性不育且自然受孕预后不良的夫妇随机分配至IVF-SET、改良自然周期IVF或IUI-OS。
  • 本分析仅使用IVF-SET(201对夫妇)与IUI-OS(207对夫妇)比较的数据。
  • 预设的潜在治疗选择标志物包括:女性年龄、种族、吸烟状态、不育类型(原发/继发)、不育持续时间、BMI、洗涤前总活动精子数和Hunault预测评分。
  • 鉴于分析的探索性,使用P值0.1。

主要发现

  • 预设的基线特征均未显示与IVF-SET相比IUI-OS获得健康孩子机会更高相关(交互作用P值>0.10)。

关键数值与推荐

  • 交互作用P值>0.10视为无统计学意义。

临床怎么用

  • 作者结论认为IUI-OS应继续作为不明原因或轻度男性不育夫妇的首选一线治疗。

局限性

  • 这是首个大型研究探讨IVF-SET相比IUI-OS的潜在治疗选择标志物,因此无数据用于样本量计算。
  • 样本量有限,难以检测到更小的关联。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: Are there treatment selection markers that could aid in identifying couples, with unexplained or mild male subfertility, who would have better chances of a healthy child with IVF with single embryo transfer (IVF-SET) than with IUI with ovarian stimulation (IUI-OS)? SUMMARY ANSWER: We did not find any treatment selection markers that were associated with better chances of a healthy child with IVF-SET instead of IUI-OS in couples with unexplained or mild male subfertility. WHAT IS KNOWN ALREADY: A recent trial, comparing IVF-SET to IUI-OS, found no evidence of a difference between live birth rates and multiple pregnancy rates. It was suggested that IUI-OS should remain the first-line treatment instead of IVF-SET in couples with unexplained or mild male subfertility and female age between 18 and 38 years. The question remains whether there are some couples that may have higher pregnancy chances if treated with IVF-SET instead of IUI. STUDY DESIGN, SIZE, DURATION: We performed our analyses on data from the INeS trial, where couples with unexplained or mild male subfertility and an unfavourable prognosis for natural conception were randomly allocated to IVF-SET, IVF in a modified natural cycle or IUI-OS. In view of the aim of this study, we only used data of the comparison between IVF-SET (201 couples) and IUI-OS (207 couples). PARTICIPANTS/MATERIALS, SETTING, METHODS: We pre-defined the following baseline characteristics as potential treatment selection markers: female age, ethnicity, smoking status, type of subfertility (primary/secondary), duration of subfertility, BMI, pre-wash total motile count and Hunault prediction score. For each potential treatment selection marker, we explored the association with the chances of a healthy child after IVF-SET and IUI-OS and tested if there was an interaction with treatment. Given the exploratory nature of our analysis, we used a P-value of 0.1. MAIN RESULTS AND THE ROLE OF CHANCE: None of the markers were associated with higher chances of a healthy child from IVF-SET compared to IUI-OS (P-value for interaction >0.10). LIMITATIONS, REASONS FOR CAUTION: Since this is the first large study that looked at potential treatment selection markers for IVF-SET compared to IUI-OS, we had no data on which to base a power calculation. The sample size was limited, making it difficult to detect any smaller associations. WIDER IMPLICATIONS OF THE FINDINGS: We could not identify couples with unexplained or mild male subfertility who would have had higher chances of a healthy child from immediate IVF-SET than from IUI-OS. As in the original trial IUI-OS had similar effectiveness and was less costly compared to IVF-SET, IUI-OS should remain the preferred first-line treatment in these couples. STUDY FUNDING/COMPETING INTEREST(S): The study was supported by a grant from the Netherlands Organization for Health Research and Development, and a grant from the Netherlands' association of health care insurers. There are no conflicts of interest. TRIAL REGISTRATION NUMBER: The trial was registered at the Dutch trial registry (NTR939).

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Tjon-Kon-Fat RI, Tajik P, Zafarmand MH, et al. IVF or IUI as first-line treatment in unexplained subfertility: the conundrum of treatment selection markers. Hum Reprod. 2017. PMID: 28333222. doi:10.1093/humrep/dex037

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。